AICPI
AVIR icon

ABG Innovation Capital Partners III’s Atea Pharmaceuticals AVIR Stock Holding History

ABG Innovation Capital Partners III’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,265,631
Closed -$27.2M – 7
2021
Q2 		$27.2M Buy
+1,265,631
New +$38M 91.01% 1
2021
Q1 		– Sell
-2,639,178
Closed -$110M – 8
2020
Q4 		$110M Buy
+2,639,178
New +$85.1M 64.92% 1

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ABG Innovation Capital Partners III's AVIR Position: Q3 2021 in Review

ABG Innovation Capital Partners III sold out of Atea Pharmaceuticals (AVIR) in Q3 2021, closing a stake of 1,265,631 shares — an estimated $27.2M sold.

ABG Innovation Capital Partners III first reported a position in AVIR in Q4 2020 and held it in 2 quarters. The position peaked at $110M in Q4 2020. 142 funds tracked by Wall St. Rank hold AVIR as of Q3 2021.

  • ABG Innovation Capital Partners III reported no remaining Atea Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • ABG Innovation Capital Partners III sold 1,265,631 Atea Pharmaceuticals shares in Q3 2021, an estimated $27.2M.
  • ABG Innovation Capital Partners III first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • ABG Innovation Capital Partners III's Atea Pharmaceuticals position peaked at $110M in Q4 2020.
  • 142 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2021.

Based on ABG Innovation Capital Partners III's 13F filing for Q3 2021, filed 15 Nov 2021.